CellaVision receives important order from a leading Canadian laboratory
(Thomson Reuters ONE) -
CellaVision, which develops and sells products for routine analysis of blood and
other body fluids in health care, has been entrusted with delivering an order of
seven automated cell morphology systems to Calgary Laboratory Services (CLS),
one of the largest multi-site integrated acute care and community laboratory
practices in North America. CLS is set to use CellaVision's solution in six of
their facilities, and will network cell morphology results and share patient
information between them.
The order comprises seven CellaVision® DM96 analyzers for peripheral blood and
body fluid analysis and the CellaVision® Remote Review Software, software which
enables connectivity between six hematology labs in Southern Alberta for the
purpose of centralizing hematology review and streamlining consultation. The
major part of the order will be delivered during September.
"The order from CLS once again confirms our ability to provide enhanced
efficiency and quality to multi-site laboratories, which are increasingly
demanded by the health care sector across the world," says Yvonne Mårtensson,
CEO of CellaVision. "Our partnership provides CLS with the tools to become best
practice in cell morphology and to aid in the delivery of high-quality care."
Calgary Laboratory Services believes that CellaVision equates to technology of
the future. In addition to creating efficiency and productivity into their
multi-site operation, it provides more flexibility in terms of morphological
assessment of samples.
"We find that it enhances our current high standard by creating increased
reproducibility and eliminating the inter-observer variation, especially among
reporting the RBC morphology", states Dr. Adnan Mansoor, Division Head of
Hematology and Transfusion Medicine at CLS. He goes on to say that "CellaVision
offers a quick comparison to previous morphology on complex patients. Adding to
the many benefits is the extensive support it will provide to the CLS teaching
program."
North America is CellaVision's most important growth market. In 2010, North
America counted for approximately 50 percent of CellaVision's total annual
sales. Since 2007, the CellaVision products are sold in Canada by the subsidiary
CellaVision Canada Inc. Efficiency has long been the most important driver for
meeting greater productivity requirements in North American laboratories. The
growing staff shortages that exist in laboratory operations in the western world
are evident in the US and Canada. Laboratories are therefore seeking solutions
that ensure effective and efficient management of their large and growing sample
volumes while minimizing response times.
For more information, please contact:
Yvonne Mårtensson, CEO, CellaVision AB
Phone: +46 708 33 77 82. E-mail:yvonne.martensson(at)cellavision.com
About CellaVision
CellaVision is an innovative, global medical technology company that develops
and sells best-in-class systems for the routine analysis of blood and other body
fluids. These analyses often provide critical results used in the diagnosis of a
variety of illnesses such as infection and cancer. CellaVision's products reduce
manual laboratory work, standardize results and support an efficient laboratory
workflow. The company has leading-edge expertise in digital image analysis,
artificial intelligence and automated microscopy. In 2010, net sales were 132
MSEK and sales continue to grow with the target to increase by at least 15 % per
year over an economic cycle. CellaVision has its head office in Lund, Sweden,
and subsidiaries in the US, Canada and Japan. The company share is listed on
Nasdaq OMX Stockholm, Small Cap. Read more atwww.cellavision.com.
This announcement is distributed by Thomson Reuters on behalf of
Thomson Reuters clients. The owner of this announcement warrants that:
(i) the releases contained herein are protected by copyright and
other applicable laws; and
(ii) they are solely responsible for the content, accuracy and
originality of the information contained therein.
Source: CellaVision AB via Thomson Reuters ONE
[HUG#1544053]
Unternehmensinformation / Kurzprofil:
Datum: 06.09.2011 - 08:00 Uhr
Sprache: Deutsch
News-ID 62562
Anzahl Zeichen: 4629
contact information:
Town:
Lund
Kategorie:
Business News
Diese Pressemitteilung wurde bisher 248 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"CellaVision receives important order from a leading Canadian laboratory"
steht unter der journalistisch-redaktionellen Verantwortung von
CellaVision AB (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
